Current role of irinotecan in the treatment of non-small-cell lung cancer.

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Lung cancer remains the primary cause of cancer-related death in both men and women in the United States. Chemotherapy has been shown to provide a survival benefit in patients with advanced non-small-cell lung cancer (NSCLC), and current regimens have produced median survivals of approximately 8 months and 1-year survival rates of 30% to 35% in patients with stage IIIB and IVdisease. Nevertheless, there remains room for improvement. Irinotecan (CPT-II, Camptosar) has demonstrated efficacy in the treatment of small-cell lung cancer (SCLC). It also appears to have promising activity in advanced NSCLC, producing overall response rates of up to 32%. Combinations of irinotecan and cisplatin or carboplatin (Paraplatin) have resulted in overall response rates of 25% to 56% in phase II and III studies in patients with advanced disease, with median survivals ranging from 9 to 13 months and 1-year survival rates of 33% to 58%. Current irinotecan-based doublet and triplet regimens appear to produce promising response rates with manageable toxicities. In addition, irinotecan has demonstrated potential as a radiosensitizing agent and is currently being evaluated in several trials of combined-modality therapy in patients with locally advanced NSCLC. Early trials of irinotecan in combination with cisplatin or carboplatin along with radiation therapy have reported overall response rates of 60% to 67%. The approach appears to have potential and warrants further study.

Original languageEnglish (US)
Pages (from-to)1153-1162, 1165
JournalOncology (Williston Park, N.Y.)
Volume16
Issue number9
StatePublished - Sep 2002
Externally publishedYes

Fingerprint

irinotecan
Non-Small Cell Lung Carcinoma
Carboplatin
Cisplatin
Survival
Therapeutics
Survival Rate
Radiation-Sensitizing Agents
Carnitine O-Palmitoyltransferase
Combined Modality Therapy
Small Cell Lung Carcinoma
Lung Neoplasms
Radiotherapy

ASJC Scopus subject areas

  • Oncology

Cite this

Current role of irinotecan in the treatment of non-small-cell lung cancer. / Kelly, Karen.

In: Oncology (Williston Park, N.Y.), Vol. 16, No. 9, 09.2002, p. 1153-1162, 1165.

Research output: Contribution to journalArticle

@article{ad40aae08da548508de5841eee272fc0,
title = "Current role of irinotecan in the treatment of non-small-cell lung cancer.",
abstract = "Lung cancer remains the primary cause of cancer-related death in both men and women in the United States. Chemotherapy has been shown to provide a survival benefit in patients with advanced non-small-cell lung cancer (NSCLC), and current regimens have produced median survivals of approximately 8 months and 1-year survival rates of 30{\%} to 35{\%} in patients with stage IIIB and IVdisease. Nevertheless, there remains room for improvement. Irinotecan (CPT-II, Camptosar) has demonstrated efficacy in the treatment of small-cell lung cancer (SCLC). It also appears to have promising activity in advanced NSCLC, producing overall response rates of up to 32{\%}. Combinations of irinotecan and cisplatin or carboplatin (Paraplatin) have resulted in overall response rates of 25{\%} to 56{\%} in phase II and III studies in patients with advanced disease, with median survivals ranging from 9 to 13 months and 1-year survival rates of 33{\%} to 58{\%}. Current irinotecan-based doublet and triplet regimens appear to produce promising response rates with manageable toxicities. In addition, irinotecan has demonstrated potential as a radiosensitizing agent and is currently being evaluated in several trials of combined-modality therapy in patients with locally advanced NSCLC. Early trials of irinotecan in combination with cisplatin or carboplatin along with radiation therapy have reported overall response rates of 60{\%} to 67{\%}. The approach appears to have potential and warrants further study.",
author = "Karen Kelly",
year = "2002",
month = "9",
language = "English (US)",
volume = "16",
pages = "1153--1162, 1165",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "9",

}

TY - JOUR

T1 - Current role of irinotecan in the treatment of non-small-cell lung cancer.

AU - Kelly, Karen

PY - 2002/9

Y1 - 2002/9

N2 - Lung cancer remains the primary cause of cancer-related death in both men and women in the United States. Chemotherapy has been shown to provide a survival benefit in patients with advanced non-small-cell lung cancer (NSCLC), and current regimens have produced median survivals of approximately 8 months and 1-year survival rates of 30% to 35% in patients with stage IIIB and IVdisease. Nevertheless, there remains room for improvement. Irinotecan (CPT-II, Camptosar) has demonstrated efficacy in the treatment of small-cell lung cancer (SCLC). It also appears to have promising activity in advanced NSCLC, producing overall response rates of up to 32%. Combinations of irinotecan and cisplatin or carboplatin (Paraplatin) have resulted in overall response rates of 25% to 56% in phase II and III studies in patients with advanced disease, with median survivals ranging from 9 to 13 months and 1-year survival rates of 33% to 58%. Current irinotecan-based doublet and triplet regimens appear to produce promising response rates with manageable toxicities. In addition, irinotecan has demonstrated potential as a radiosensitizing agent and is currently being evaluated in several trials of combined-modality therapy in patients with locally advanced NSCLC. Early trials of irinotecan in combination with cisplatin or carboplatin along with radiation therapy have reported overall response rates of 60% to 67%. The approach appears to have potential and warrants further study.

AB - Lung cancer remains the primary cause of cancer-related death in both men and women in the United States. Chemotherapy has been shown to provide a survival benefit in patients with advanced non-small-cell lung cancer (NSCLC), and current regimens have produced median survivals of approximately 8 months and 1-year survival rates of 30% to 35% in patients with stage IIIB and IVdisease. Nevertheless, there remains room for improvement. Irinotecan (CPT-II, Camptosar) has demonstrated efficacy in the treatment of small-cell lung cancer (SCLC). It also appears to have promising activity in advanced NSCLC, producing overall response rates of up to 32%. Combinations of irinotecan and cisplatin or carboplatin (Paraplatin) have resulted in overall response rates of 25% to 56% in phase II and III studies in patients with advanced disease, with median survivals ranging from 9 to 13 months and 1-year survival rates of 33% to 58%. Current irinotecan-based doublet and triplet regimens appear to produce promising response rates with manageable toxicities. In addition, irinotecan has demonstrated potential as a radiosensitizing agent and is currently being evaluated in several trials of combined-modality therapy in patients with locally advanced NSCLC. Early trials of irinotecan in combination with cisplatin or carboplatin along with radiation therapy have reported overall response rates of 60% to 67%. The approach appears to have potential and warrants further study.

UR - http://www.scopus.com/inward/record.url?scp=0036730215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036730215&partnerID=8YFLogxK

M3 - Article

C2 - 12380945

AN - SCOPUS:0036730215

VL - 16

SP - 1153-1162, 1165

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 9

ER -